DADUN
Correction: Ordoñez, et al.; DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters? Cancers 2019, 11, 1424
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Molecular profiling of immunoglobulin heavychain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1b Study of Isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
